Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma

A study published in Blood found that the success of the T-cell engager glofitamab in relapsed or refractory large B-cell lymphoma (LBCL) depends heavily on the health and strength of a patient’s T cells. Researchers analyzed patients from the Phase 1/2 NP30179 trial and discovered that patients who responded well to treatment maintained higher levels of […]

Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma Read More »

INBRX-106 Plus Keytruda Doubles Response Rate in Advanced Head and Neck Cancer Trial

Interim results from the Phase 2 HexAgon study showed that adding the OX40 agonist INBRX-106 to Keytruda improved outcomes for patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination treatment achieved a confirmed overall response rate of 44%, compared with 21.4% for Keytruda alone. Three patients receiving the combination therapy had a

INBRX-106 Plus Keytruda Doubles Response Rate in Advanced Head and Neck Cancer Trial Read More »

New PSMA Radioligand Therapy Shows Strong Results in Advanced Prostate Cancer Trial

A Phase 1 study found that the new radioligand therapy [177Lu]Lu-D-Dan-Phe-PSMA is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC). The treatment was designed to stay in the body and tumors longer than current therapies such as Pluvicto, allowing it to deliver more radiation directly to cancer cells. In the highest dose

New PSMA Radioligand Therapy Shows Strong Results in Advanced Prostate Cancer Trial Read More »

Real-World Study Shows Zanubrutinib Improves Outcomes in Mantle Cell Lymphoma

A real-world study of patients with relapsed or refractory mantle cell lymphoma (MCL) found that the drug Brukinsa may work better than older BTK inhibitors. Researchers reported that patients treated with zanubrutinib in second- or third-line therapy lived longer compared with those treated with Imbruvica. The study also showed that patients taking zanubrutinib went longer

Real-World Study Shows Zanubrutinib Improves Outcomes in Mantle Cell Lymphoma Read More »

SurVaxM Vaccine Enters Phase 2 Trial for Neuroendocrine Tumors

MimiVax Inc. and Roswell Park Comprehensive Cancer Center have started a Phase 2 clinical trial to test the cancer vaccine SurVaxM in patients with worsening neuroendocrine tumors (NETs). The study will compare SurVaxM plus the chemotherapy drug temozolomide with temozolomide alone. SurVaxM is designed to help the immune system attack survivin, a protein linked to

SurVaxM Vaccine Enters Phase 2 Trial for Neuroendocrine Tumors Read More »

Experimental Therapy Starves Cancer Cells by Blocking Energy Production

Researchers have developed an experimental cancer therapy called aurB that kills tumors by blocking their energy production. Inspired by bacteria living inside tumors, scientists created aurB from a bacterial protein called auracyanin. The therapy targets mitochondria, the cell’s energy source, and blocks ATP synthase, an enzyme needed to produce energy. Without energy, cancer cells struggle

Experimental Therapy Starves Cancer Cells by Blocking Energy Production Read More »

New Targeted ADC Therapies Show Promise in Advanced Lung Cancer Treatment

Antibody-drug conjugates (ADCs) are changing the treatment of advanced non-small cell lung cancer (NSCLC) by delivering chemotherapy directly to cancer cells while reducing damage to healthy tissue. Doctors say these targeted therapies are showing better results than traditional second-line chemotherapy such as docetaxel, which has limited response rates. Medical oncologist Judy Wang explained that ADCs

New Targeted ADC Therapies Show Promise in Advanced Lung Cancer Treatment Read More »

Cancer Experts Warn Biotin Supplements May Interfere With Critical Blood Tests

Doctors are warning cancer patients to be cautious about taking biotin supplements for hair and nail growth because the vitamin can interfere with important blood tests. Although biotin, also known as vitamin B7, is often promoted online as a harmless beauty supplement, experts say it can create misleading lab results that may affect cancer care.

Cancer Experts Warn Biotin Supplements May Interfere With Critical Blood Tests Read More »

New Lipid Profiling Method Shows Promise for Early Pancreatic Cancer Detection

Researchers have developed a new lipid analysis method that could improve early detection of pancreatic cancer by identifying hidden changes in blood fat molecules. The technique combines advanced mass spectrometry with specialized software to detect detailed lipid structures that standard tests often miss. The study analyzed 15 lipid classes, including ceramides and sphingomyelins, using a

New Lipid Profiling Method Shows Promise for Early Pancreatic Cancer Detection Read More »

FDA Approves Bizengri for Rare NRG1-Positive Bile Duct Cancer

The FDA has approved Zenocutuzumab (Bizengri) for adults with advanced bile duct cancer linked to rare $NRG1$ gene fusions after previous treatments stopped working. The approval gives a new option to patients with this ultra-rare form of cholangiocarcinoma, a cancer that usually has very limited treatment choices. The decision was based on results from the

FDA Approves Bizengri for Rare NRG1-Positive Bile Duct Cancer Read More »